Leukemia & Lymphoma

Article	Citations
The prognostic role of gene polymorphisms in patients with indolent non-Hodgkin lymphomas and mantle-cell lymphoma receiving bendamustine and rituximab: results of the 5-year follow-up study	49
Impact of SF3B1 mutation in myelofibrosis	44
Pulmonary infections in patients with acute myeloid leukemia receiving frontline treatment with hypomethylating agents	30
The mechanism of action, pharmacological characteristics, and clinical utility of the amyloid depleter birtamimab for the potential treatment of AL amyloidosis	28
CD274 structural variants for guiding treatment with PD-1 blockade in a patient with relapsed/refractory chronic active EBV transformed to NK lymphoma	26
Evaluating early response assessment in extranodal natural killer/T-cell lymphoma by analyzing ΔSUVlbm between baseline and interim 18 F-FDG PET/CT scans	25
Treatment outcomes of venetoclax-combination regimens for relapsed/refractory myeloid malignancies after anti-CD47-directed therapy	23
Risk factors for mortality and re-admission of children with hematological malignancies to the intensive care unit due to sepsis	22
Blinatumomab for the treatment of acute lymphoblastic leukemia in a real-world setting: clinical vignettes	22
Real-world associations of cytokine release syndrome and neurotoxicity with efficacy in patients receiving anti-CD-19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma: the Mayo Clini	21
Organ toxicities associated with chimeric antigen receptor T-cell therapy	20
The effect of the plasma methotrexate concentration during high-dose methotrexate therapy in childhood acute lymphoblastic leukemia	20
Incidence of major bleeding in patients with chronic lymphocytic leukemia receiving ibrutinib and therapeutic anticoagulation	18
Hypereosinophilia after CAR T-cell therapy	18
Transplantation provides superior survival high risk myeloid malignancies in older patients	17
Complete remission in a case of acute undifferentiated leukemia with novel combination therapy of FLAG-IDA and venetoclax	17
Risk factors for the development of orthostatic hypotension during autologous stem cell transplant in patients with multiple myeloma	17
Shift in first-line therapies for United States Veterans Affairs (VA) patients with chronic lymphocytic leukemia (CLL)	17
Use of PD-1 blockade in refractory/relapsed natural killer T-cell lymphomas: a systematic review and synthesis of case reports	16
Indolent B-cell non-Hodgkin lymphomas in children: high association with inborn errors of immunity	16
The inherited genetic contribution and polygenic risk score for risk of CLL and MBL: a narrative review	15
CRLF2 and IKZF1 abnormalities in childhood hematological malignancies other than B-cell Acute Lymphoblastic Leukemia	15
New therapies for angioimmunoblastic T-cell lymphoma: a comprehensive review and analysis	15
Embelin inhibits viability of cutaneous T cell lymphoma cell lines HuT78 and H9 by targeting inhibitors of apoptosis	15
Cigarette smoking is associated with worse prognosis in myelodysplastic syndromes and hematopoietic alterations in murine models	15

T-cell/histiocyte-rich large B-cell lymphoma, insights into prognosis and treatment complexity in the context of immunotherapeutics	14
MRD dynamics during maintenance therapy in 259 patients with nontransplant eligible multiple myeloma	14
Results from an open-label phase 2a study of cerdulatinib, a dual spleen tyrosine kinase/janus kinase inhibitor, in relapsed/refractory peripheral T-cell lymphoma	14
Carfilzomib in combination with R-CHOP for initial treatment of patients with non-germinal center diffuse large B-cell lymphoma: a multicenter, single arm, phase 1/2 study	14
High seroconversion rates amongst black and Hispanics with hematologic malignancies after SARS-CoV-2 vaccination	14
Dupilumab for the treatment of refractory lenalidomide rash in patients with multiple myeloma	14
XX International workshop on chronic lymphocytic leukemia	13
Ruxolitinib bridging therapy to allogeneic SCT for high-risk refractory subcutaneous panniculitis-like T-cell lymphoma	13
ELN 2025 and somatic NGS in CML: a pragmatic framework for selective testing and interpretation beyond BCR::ABL1	13
CD69 marks a subpopulation of acute myeloid leukemia with enhanced colony forming capacity and a unique signaling activation state	13
Efficacy and safety of voriconazole as invasive fungal infection prophylaxis in patients with acute myeloid leukemia	13
The maturing picture of CPX-351 in acute myeloid leukemia: long-term real-world experience with CPX-351 treatment for acute myeloid leukemia in England	12
Rare HNRNPH1::ERG rearrangement in a case of de novo pediatric AML and review of cases	12
Chemotherapy-free approach with arsenic trioxide and all-trans retinoic acid in children with acute promyelocytic leukemia	12
Management of relapsed/refractory mantle cell lymphoma	12
Matching-adjusted indirect comparison of axi-cel and liso-cel in relapsed or refractory large B-cell lymphoma	12
Progressive eosinophilia and STAT5B mutation acquisition in AML treated with azacitidine and venetoclax	12
Homocysteine-driven oxidative stress in pediatric lymphoma: a cross-sectional study of metabolic and genetic modulators	12
Successful treatment with bortezomib, thalidomide and dexamethasone in plasma cell myeloma post-bone marrow transplant	12
Targeting the IL-8 axis in high-risk myelodysplastic syndromes: a clinical experience with antibody blockade combined with decitabine/cedazuridine	12
Asparaginase therapy in patients with acute lymphoblastic leukemia: expert opinion on use and toxicity management	12
Transforming growth factor beta receptor type I (TGF-βRI) kinase inhibitors IOA-359 and IOA-360 stimulate erythropoiesis in MDS	12
Evaluation of non-research and research industry payments to pediatric hematologist/oncologists in the United States between 2013 and 2021	12
Differential responses to sequential menin inhibitor therapy for acute leukemia underscore the complexities of acquired resistance	12
Analysis of albumin as a prognostic factor in HHV-8/HIV-negative Castleman disease from a multicenter study	11
MicroRΝΑ analysis in patients with myelodysplastic neoplasms. Possible implications in risk stratification	11
Successful treatment with belantamab mafodotin in a heavily pretreated patient with multiple myeloma and liver extramedullary disease	11
Hyperleukocytosis associated with delayed presentation among patients with acute leukemia during the COVID-19 pandemic	11
Association between plasma venetoclax trough levels and serum C-reactive protein levels in patients with acute myeloid leukemia treated with venetoclax plus azacitidine	11
Mutational landscape in Waldenström macroglobulinemia evaluated using a next-generation sequencing lymphoma panel in routine clinical practice	11
CAR-T cell therapy in the treatment of relapsed or refractory primary central nervous system lymphoma: recent advances and challenges	11
State-wise disparities and temporal trends in acute myeloid leukemia (AML) in the United States of America (USA)	11
Clinical outcomes of allogeneic cell transplantation for patients with chronic myeloid leukemia	11
Treatment choice for chronic lymphocytic leukemia after covalent BTKi therapy: a patient and oncologist preference study	10
Donor-derived somatic genetic rescue with prolonged hematopoietic stability following sibling allogeneic stem cell transplant in SAMD9 syndrome	10
Olverembatinib in relapsed Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia: a study of 5 cases	10
Allogeneic hematopoietic stem cell transplantation following T-cell-directed immunotherapy failure in B-cell lymphoma: a real-world case series and systematic literature review	10
Expanding the phenotypic spectrum of DDX41-related myeloid neoplasms: a case of mature plasmacytoid dendritic cell proliferation associated with acute myeloid leukemia with germline DDX41 mutation	10
Richter transformation – retrospective treatment outcomes analysis in Polish Adult Leukemia Study Group	10
Cost-Effectiveness of brexucabtagene autoleucel for relapsed/refractory mantle cell lymphoma	10
Prediction of relapse after discontinuation of tyrosine kinase inhibitor treatment in CML	10
Venetoclax-based induction therapy for primary plasma cell leukemia with high BCL-2 expression	10
Single versus tandem autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma and high-risk cytogenetics. A retrospective, open-label study of the PETHEMA/Spanish Myeloma	10
Single-center retrospective study assessing the efficacy and safety of BeEAM (bendamustine, etoposide, cytarabine, melphalan) as conditioning regimen for autologous hematopoietic stem cell transplanta	10
CML stem cells and their interactions and adaptations to tyrosine kinase inhibitors	10
Megakaryocyte centrosomal and Golgi structural perturbations in patients with primary myelofibrosis and with RUNX1 germline mutation	10
Disease response upon cessation of methotrexate in a patient with Hodgkin lymphoma treated with pembrolizumab	9
Optimal conditioning intensity: favorable outcome of a 3-day busulfan based regimen in younger acute myeloid leukemia patients	9
Impact of chronic graft- versus -host disease on non-relapse mortality and survival	9
Intake of benzodiazepines in treatment naïve chronic lymphocytic leukemia patients is associate with a shorter time to first treatment	9

Sun protection behaviors among adult survivors receiving hematopoietic cell transplantation: a cross-sectional survey of a single institution in Japan	9
Denosumab versus intravenous bisphosphonate use for hypercalcemia in multiple myeloma	9
The characterization and the impact of CSF pleocytosis during blinatumomab therapy for adult acute lymphoblastic leukemia	9
Ph-like acute lymphoblastic leukemia in adults: understanding pathogenesis, improving outcomes, and future directions for therapy	9
Prospects for liquid biopsy approaches in lymphomas	9
Rebound of COVID-19 infection in patients with chronic lymphocytic leukemia treated for SARS-CoV-2 with Nirmatrelvir/Ritonavir or Molnupiravir	9
Use of a real-world synthetic control arm for direct comparison of lisocabtagene maraleucel and conventional therapy in relapsed/refractory large B-cell lymphoma	9
Low-risk relapsed acute lymphoblastic leukemia in children and young adults: what have we learnt and what’s next?	9
The diagnosis of Burkitt lymphoma: how do pathologists apply criteria in daily practice?	9
Off-label use of recombinant activated factor VII in hemophagocytic lymphohistiocytosis patients with major bleeding	9
Correction	9
Outcomes and patterns of relapse with ponatinib-based therapy in patients with chronic myeloid leukemia in myeloid blast phase	9
Prognostic impact of TP53 mutations in adult acute lymphoblastic leukemia treated with a pediatric-type regimen	9
Factors associated with long-term quality of life after allogenic stem cell transplantation	9
Effectiveness and safety of leukapheresis in hyperleukocytic leukemias: a retrospective multicenter study	9
COVID-19 antibody titers after tixagevimab–cilgavimab injection in patients with hematologic diseases; a single-center, prospective study	9
MEIS inhibitors reduce the viability of primary leukemia cells and Stem cells by inducing apoptosis	9
Achievement of durable remission of relapsed/refractory acute myeloid leukemia in a child using venetoclax monotherapy	9
[ 211 At]astatine-based anti-CD22 radioimmunotherapy for B-cell malignancies	9
Pre- and post-transplant extramedullary involvement in adult patients with t(8;21)(q22;q22) acute myeloid leukemia: incidence, risk factors and outcomes	9
Mitigating time toxicity in lymphoma and multiple myeloma	8
Improved overall survival over time in advanced stage mycosis fungoides: a cross-sectional study	8
Emerging drug profile: JAK inhibitors	8
Response to trametinib of two pediatric myeloid malignancies cases harboring RAS mutation and monosomy 7	8
Clinicopathologic and genetic evaluation of B-lymphoblastic leukemia with intrachromosomal amplification of chromosome 21 (iAMP21) in adult patients	8
Managing myelofibrosis in the frailty era: the expanding role of JAK inhibitors	8
Therapy with mosunetuzumab, a bispecific antibody for relapsed/refractory hairy cell leukemia	8
The challenge of targeting key drivers of CLL and sequencing therapy in an era of experimental therapeutics	8
Ixazomib-induced thrombotic microangiopathy resolving without complement pathway inhibition: a case report	8
TP53 -altered higher-risk myelodysplastic syndromes/neoplasms and acute myeloid leukemia: a distinct genetic entity with unique unmet needs	8
Efficacy of CD19 CAR T-cell therapy in active vitreoretinal lymphoma	8
CCND2 mutations in atypical chronic myeloid leukemia: a report of two cases	8
Lenalidomide, rituximab (R 2 ), and ixazomib for frontline treatment of high risk follicular and indolent non-Hodgkin lymphoma	8
The International Prognostic Score and HIV status predict red cell concentrate transfusion needs in Hodgkin lymphoma	8
Two recurrent types of IGH ::5′ BCL2 breakpoints representing cytogenetic ins(14;18)(q32;q21q21) and t(14;18)(q32;q21), mediated by the	8
Healthcare resource use and reimbursement amount by site of care in patients with diffuse large B-cell lymphoma receiving chimeric antigen receptor T-cell (CAR-T) therapy – a retrospective cohort stud	8
Prephase steroid use and association with dose delays and outcomes in a real-world cohort of older adults treated for diffuse large B-cell lymphoma	8
Clinical characteristics and outcomes of Brazilian patients with duodenal-type follicular lymphoma: a multicenter retrospective study	8
Familial aspects of multiple myeloma and Waldenström macroglobulinemia: understanding the predisposition in relatives and the importance of early diagnosis	8
Allogeneic stem cell transplant outcomes between TBI-containing reduced intensity and myeloablative conditioning regimens for ALL in complete remission	8
Prevalence and clinicopathological features of incidentally detected TRBC1-dim populations in peripheral blood flow cytometry	8
The impact of marginalization on diffuse large B-cell lymphoma overall survival: a retrospective cohort study	8
Azacitidine and venetoclax with or without pevonedistat in patients with newly diagnosed acute myeloid leukemia	8
A phase 1 study of interleukin-15 in combination with avelumab in relapsed or refractory T-cell lymphoma	8
When evaluating targeted therapies in chronic lymphocytic leukemia, the absolute measure of treatment effect should be preferred	8
Carfilzomib, daratumumab, and dexamethasone (KdD) vs. lenalidomide-sparing pomalidomide-containing triplet regimens for relapsed/refractory multiple myeloma: an indirect treatment comparison	8
Prognostic relevance of the neutrophil/lymphocyte ratio in diffuse large B-cell lymphoma: a systematic review and meta-analysis and dose–response evidence	8
Hemoglobin changes during long-lasting frontline treatment with Tyrosine-Kinase inhibitors in patients with chronic myeloid leukemia	7
Spinal cord disease following CAR T-cell therapy with axicabtagene ciloleucel in a patient with high-grade B-cell lymphoma	7
Relapsed and refractory peripheral T-cell lymphoma; treatment, challenges and future perspectives	7
Inter-racial genetic differences in myelofibrosis: a diverse inner-city center analysis	7
Characteristics and clinical behavior of acute myeloid leukemia harboring rare non-A/B/D nucleophosmin ( NPM1 ) gene mutation subtypes: a single-center experience and re	7
White blood cell count nadir to zero following intensive chemotherapy as a predictive factor for patients with acute myeloid leukemia	7
Effects of fludarabine dosage on transplant-related outcomes in hematopoietic stem cell transplantation	7
Immunohistochemistry-based detection of TP53 mutations in acute myeloid leukemia: a promising high sensitivity diagnostic approach	7
Challenging diagnosis of chronic myelomonocytic leukemia (CMML) in a patient with Takayasu arteritis: case report	7
Optimizing pegaspargase therapy in patients with hypersensitivity reactions	7
A Shared Care Model between community and transplant centers facilitates access to allogeneic and autologous transplantation	7
Successful treatment of acquired von Willebrand syndrome secondary to low-grade CLL with rituximab and venetoclax	7
Sepsis and mucositis-related biomarkers in adult hematologic patients with febrile neutropenia	7
Measurable residual disease dynamics holding prognostic significance in pediatric patients with RUNX1::RUNX1T1 -positive AML: results from AML-CAMS seria	7
Lack of a caregiver is associated with shorter survival in myeloma patients undergoing autologous stem cell transplantation	7
Recipient polymorphism of the C-reactive protein (CRP) gene rs2794521 stratified disease-free survival, but did not influence maximum serum CRP levels during neutropenia after single-unit cord blood t	7
Indolent relapse after initial aggressive B-cell lymphoma: a single institution experience in the rituximab era	7
Impact of the addition of rituximab in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia	7
Risk prediction model and survival analysis of adult patients with intracranial hemorrhage in acute leukemia	7
Single and multiple point NRAS mutations in acute myeloid leukemia: a study of 327 well molecularly characterized patients	7
CALR -mutated myeloproliferative neoplasms	7
CD5- B-cell lymphocytic leukemia –a diagnostic exclusion of splenic B-cell leukemia with prominent nuclei challenging current international consensus	6
Myeloid/lymphoid neoplasm with a novel cryptic RBPMS::FGFR1 rearrangement presenting as de novo acute leukemias	6
Genomic landscape of T-large granular lymphocyte leukemia and chronic lymphoproliferative disorder of NK cells: a single institution experience	6
Progressive TP53 inactivation in an aggressive splenic diffuse red pulp small B-cell lymphoma	6
Leukocytosis and MPNs: Where do we stand?	6
Sensitivity, specificity, and accuracy of molecular profiling on circulating cell-free DNA in refractory or relapsed multiple myeloma patients, results of MM-EP1 study	6
Apoptotic colitis secondary to Brentuximab Vedotin: an immune mediated adverse event responsive to steroid treatment	6
Primary plasma cell leukemia in Latin America: demographic, clinical, and prognostic characteristics. A study of GELAMM group	6
Lower intensity regimens for acute myeloid leukemia: opportunities and challenges	6
Lineage switch from B-ALL to AML via an intervening MDS/MPN phase with acquisition of RBM15::MKL1 and RAD21	6
Evaluation of a safe neutrophil count for cessation of intravenous antibiotics and early hospital discharge in stable, afebrile patients recovering after acute myeloid leukemia therapy or an autograft	6
Clinical and radiological prediction models for random skin biopsy positivity in suspected intravascular large B-cell lymphoma: development and internal validation	6

Characterization of the calcineurin inhibitor pain syndrome in patients undergoing allogeneic hematopoietic cell transplantation	6
Preclinical and clinical evaluation of Buparlisib (BKM120) in recurrent/refractory Central Nervous System Lymphoma	6
KLF2 double variants (C274Y and H210N) in a splenic B-cell lymphoma/leukemia: diagnostic insights into splenic marginal zone lymphoma and mechanistic implications	6
A de novo germline RUNX1 variant preceding development of concurrent T-lymphoblastic leukemia and myelodysplastic syndrome	6
Patterns of care and outcomes of early stage I–II Hodgkin lymphoma treated with or without radiation therapy	6
Labile CD22 and CD19 expression in a case of Philadelphia chromosome-like acute lymphoblastic leukemia	6
Mutational patterns in therapy-related acute lymphoblastic leukemia subgroups: one step closer to unveiling the genetic odyssey	6
Use of endpoints in phase III randomized controlled trials for acute myeloid leukemia over the last 15 years: a systematic review	6
A phase 1b study of atezolizumab in combination with guadecitabine for the treatment of acute myeloid leukemia	6
Glycated hemoglobin (HbA1c) and thrombotic risk in polycythemia vera and essential thrombocythemia	6
Moving beyond traditional clinical trial endpoints: patient-reported outcomes illuminate the patient experience of novel AML therapies	6
Daratumumab bortezomib and dexamethasone in transplant ineligible newly diagnosed elderly myeloma patients (AMN006)—a trial by Asian Myeloma Network (NCT03695744)	6
Precision and strategic targeting of novel mutation-specific vulnerabilities in acute myeloid leukemia: the semi-centennial of 7 + 3	6
Retrospective multicenter comparative study of the efficacy and safety between R-DHAC and R-DHAOx in diffuse large B-cell lymphoma or transformed follicular or marginal zone B lymphoma into aggressive	6
Real-world treatment adherence and persistence of FLT3 inhibitors as post-alloHCT maintenance therapy in patients with AML in the United States: a cohort study using administrative claims data	6
Therapeutic approach to patients with early stage diffuse large B cell lymphoma: retrospective, multicenter, real-life study of the ‘RTL’ (regional Tuscan lymphoma network)	6
Consistency of the efficacy of immunotherapy with histamine dihydrochloride and low-dose interleukin-2 for relapse prevention in acute myeloid leukemia	6
Reduced prognostic value of beta-2-microglobulin for time to first treatment in CLL patients with compromised kidney function	6
Sequential occurrence of chronic myeloproliferative and lymphoproliferative neoplasms: a collaborative retrospective study by pH-negative MPN latial group	6
Stem cell allografting for chronic Myeloid leukemia in the tyrosine kinase era – forgotten but not gone	6
XXI International Workshop on CLL 2025	6
Open-label, phase 2 study of blinatumomab after frontline R-chemotherapy in adults with newly diagnosed, high-risk DLBCL	6
Ixazomib in addition to chemotherapy for the treatment of acute myeloid leukemia in older adults	6
Normal and malignant cells are homogeneously distributed in the bone marrow of children	6
Distinct immune-response profile of Richter transformation chronic lymphocytic leukemia (CLL), defined by high expression of PD1, LAG3, TIM3 and IL-10	6
Evaluation of pulmonary toxicities in lymphoma patients receiving brentuximab vedotin	6
Response-adapted de-escalation of radiotherapy in pediatric Hodgkin’s lymphoma	6
Follicular lymphoma of the lower female genital tract: an indolent and localized extranodal follicular lymphoma with mutation of TNFRSF14	6
HHV8-Negative Effusion-Based lymphoma in a patient with recurrent HCV hepatitis status post liver transplantation	6
Hepatic Veno-occlusive disease (VOD) in multiple myeloma patient receiving Belantamab Mafodotin	6
Integrated genomic and single-cell transcriptomic analyses reveal clonal evolution and immune signature in donor cell leukemia after haploidentical allogeneic hematopoietic stem cell transplantation	5
The spectrum of tonsillar involvement in chronic lymphocytic leukemia (CLL)	5
Patients with plasma cell disorders undergoing autologous stem cell transplant retain their humoral response to COVID-19 vaccination but falling titers emphasize the importance of re-vaccination	5
A novel ETV6::FGFR1 fusion gene in a myeloid/lymphoid neoplasm with FGFR1 rearrangement sensitive to speci	5
Temporal improvements in survival with persistent disparities in acute myeloid leukemia: a two-decade population-based analysis from the United States	5
Successful treatment with zanubrutinib for Bing-Neel syndrome progressing on ibrutinib: a case report and literature review	5
The pretreatment Controlling Nutritional Status score is an independent prognostic factor in elderly patients with diffuse large B-cell lymphoma	5
Chronic lymphocytic leukemia transdifferentiated to blastic neoplasm with T/plasmacytoid dendritic cell immunophenotype	5
Predictors of cytopenias after treatment with axicabtagene ciloleucel in patients with large B-cell lymphoma	5
Calcific tendinopathy: an unexpected side effect of tyrosine kinase inhibitor?	5
EZH2 inhibitor DZNep blocks cell proliferation of GCB-DLBCL cells by upregulating p16	5
Pneumocystis jirovecii pneumonia with use of brentuximab vedotin in treatment-naïve Hodgkin lymphoma	5
Insurance-based disparities impact survival outcomes in Waldenström macroglobulinemia within the United States	5
Consecutive day dosing of high-dose cytarabine consolidation over 3 days is resource-efficient and safe in older adult patients with acute myeloid leukemia	5
Comparison of CALGB 10403 and HyperCVAD in the treatment of Philadelphia chromosome negative acute lymphoblastic leukemia in adults ≥40 years old	5
Treatment of relapsed and refractory Waldenstrom Macroglobulinemia	5
A novel murine syngeneic CD8 peripheral T-cell lymphoma model with preclinical applications	5
EBV-positive PCNSL in older patients: incidence, characteristics, tumor pathology, and outcomes across a large multicenter cohort	5
Pre-diagnostic serum concentrations of free light chains and risk of non-Hodgkin lymphoma in a population-based prospective study	5
Correction	5
Polymerase chain reaction in the diagnosis of invasive aspergillosis: approaches for appropriate use	5
Severe toxicity, but long-term persistence of CAR T cells after immune checkpoint inhibitors in large B-cell lymphoma	5
The prognostic role of NKG2A expression for patients with chronic myeloid leukemia after treatment discontinuation	5
Quercetin induces apoptosis and autophagy in pediatric acute lymphoblastic leukemia by regulating miR-367/KLF4/JNK signaling axis	5
Allogeneic hematopoietic stem cell transplantation in adult with acute lymphoblastic leukemia: evolving indications and modalities in shifting landscape	5
Endothelial activation and stress index (EASIX) to predict engraftment syndrome after autologous hematopoietic cell transplantation in patients with multiple myeloma. A single center experience	5
Acalabrutinib is an effective treatment for immune thrombocytopenia associated with chronic lymphocytic leukemia, a case report	5
The challenge of non-transplant eligible, newly diagnosed multiple myeloma	5
Off-label venetoclax in combination with hypomethylating agents for post-allogeneic stem cell transplant acute myeloid leukemia relapse	5
Therapeutic approaches for the management of higher risk myelodysplastic syndromes	5
Follicular lymphoma: an update on biology and optimal therapy	5
TP53/PLCG2-mutated diffuse large B-cell lymphoma richter transformation (DLBCL-RT) of CLL with unusual CD2 and PD-1 expression	5
Beyond “favorable”: early molecular response and outcomes in pediatric RUNX1::RUNX1T1 AML	5
Racial disparities in multiple myeloma: biological heterogeneity, treatment access, and prognostic implications	5
A retrospective analysis of factors impacting survival in United States military veterans with multiple myeloma	5
A randomized phase II/III study of ‘novel therapeutics’ versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomono	5
Stereotactic radiotherapy and CART for treatment of secondary CNS lymphoma	5
Sarcopenia is a prognostic factor in lymphoma patients: a systematic review and meta-analysis	5
Autologous stem cell transplant for multiple myeloma: Impact of melphalan dose on the transplant outcome	5
Olverembatinib and high-dose methotrexate in acute lymphoblastic leukemia: delayed methotrexate clearance and increased nephrotoxicity	5
Novel treatment for mantle cell lymphoma – impact of BTK inhibitors and beyond	5
Targeting the immune microenvironment in mantle cell lymphoma: implications for current and emerging therapies	5
The characteristics and clinical prognosis analysis of ASXL1 mutations in Chinese adult patients with primary cytogenetically normal acute myeloid leukemia by next-generation sequencing	5
Innovative management of BK virus nephropathy post-HSCT: a case report and therapeutic insights	5
Comparative analysis of hypomethylating agents as maintenance therapy after allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia	5
Cytarabine dose intensification improves survival in older patients with secondary/high-risk acute myeloid leukemia in matched real-world versus clinical trial data	5
Epcoritamab for diffuse large B-cell lymphoma in a dialysis-dependent patient	5
Response to ‘blast identification in cerebrospinal fluid specimens from patients with acute myeloid leukemia: laboratory perspectives’	5
A case of testicular diffuse large B-cell lymphoma with late relapse in the skin: the critical role of comparative phenotypic, clonality, and cytogenetic testing	5
Phase 1b, open-label study evaluating the safety and pharmacokinetics of atezolizumab (anti–PD-L1 antibody) administered in combination with Hu5F9-G4 to patients with relapsed and/or refractory acute	5
Factors affecting treatment decisions for lower-risk myelodysplastic syndromes across practice settings	5
Diffuse large B-cell lymphoma outcomes in an urban safety-net cohort: functional status, clinical risk, and treatment feasibility	5
Correction	4
Gammopathic dermopathy: characterization of cutaneous MGUS	4
First clinical description of a pedigree with complete NAF1 deletion	4
Acute neurologic deterioration in a patient with asymptomatic Charcot-Marie-Tooth disease following three doses of Brentuximab-Vedotin	4
Matching-adjusted indirect comparison of lisocabtagene maraleucel versus axicabtagene ciloleucel for second-line treatment of patients with early relapsed or refractory large B-cell lymphoma	4
Correction	4
Adverse outcomes and high incidence of therapy-related neoplasms in patients with the t(16;21)/ RUNX1 :: RUNX1T3	4
Effect of anti-CD38 monoclonal antibodies on hepatitis C virus replication in chronically infected patients with multiple myeloma: a prospective series	4
Time to omit interim CT imaging during frontline chemoimmunotherapy for patients with follicular lymphoma?	4
Next-generation sequencing of TCR clonality discriminates tumor-stage mycosis fungoides from coexisting CD30+ lymphoproliferative disorders	4
Real-world treatment patterns for patients with newly diagnosed multiple myeloma in Alberta, Canada	4
Octreotide as prophylaxis against asparaginase-associated pancreatitis: a case series study	4
SARS-CoV-2 infection in patients with primary central nervous system lymphoma in the vaccination era	4